Category
ANTI-GONADOTROPIN API
ANTI-GONADOTROPIN API
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Relugolix API has been developed by ASANA Pharmaceutical as part of its advanced hormonal therapy segment. Relugolix API, registered under CAS number 737789-87-6, is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of prostate cancer and uterine fibroids through hormonal suppression.
ASANA Pharmaceutical is focused on the development and manufacturing of high-purity hormonal therapy APIs such as Relugolix. With specialized capabilities in endocrine and oncology-related actives, ASANA ensures every batch meets international regulatory and therapeutic standards. The company delivers reliable and compliant supply across North America, Europe, and Asia through advanced infrastructure and a quality-first approach.
ASANA Pharmaceutical collaborates with clinical partners and formulation experts in hormone-sensitive treatment areas, offering precision-driven support from R&D to commercialization. Relugolix [CAS No. 737789-87-6] is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to suppress hormonal signals in conditions such as prostate cancer and uterine fibroids. It plays a vital role in ASANA’s hormone-regulating API portfolio. As demand for non-surgical, targeted hormonal therapies grows globally, ASANA is committed to delivering:
Relugolix API are available on public databases such as Wikipidia!